Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Listen in the Podli app 🎧

Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.

Featuring an interview with Dr L Elizabeth Budde, including the following topics:

Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)